Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling

[1]  Juan Yang,et al.  Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling , 2013, Proteome Science.

[2]  Yun-Fei Xia,et al.  Identifying FGA peptides as nasopharyngeal carcinoma‐associated biomarkers by magnetic beads , 2012, Journal of cellular biochemistry.

[3]  Juan Yang,et al.  Detection of serum tumor markers in multiple myeloma using the CLINPROT system , 2012, International Journal of Hematology.

[4]  F. Lo‐Coco,et al.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. , 2012, Blood.

[5]  Torsten Haferlach,et al.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Lo‐Coco,et al.  Modern approaches to treating acute promyelocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Kurzrock,et al.  Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy , 2011, International journal of hematology.

[8]  J. Moffat,et al.  The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. , 2010, Blood.

[9]  G. Netto,et al.  The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. , 2010, Urology.

[10]  Jeffrey W. Smith,et al.  Mass Spectrometry-Based Label-Free Quantitative Proteomics , 2009, Journal of biomedicine & biotechnology.

[11]  Kun He,et al.  Identification of complement C3f‐desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment , 2010, Proteomics.

[12]  M. Iyo,et al.  A search for novel markers of alcohol abuse using magnetic beads and MALDI‐TOF/TOF mass spectrometry , 2009, Proteomics. Clinical applications.

[13]  G. Mufti,et al.  Serum profiling reveals distinctive proteomic markers in chronic myeloid leukaemia patients , 2009, British journal of haematology.

[14]  Hong-ying Liu,et al.  Optimization of magnetic beads for maldi-TOF MS analysis. , 2009, Frontiers in bioscience.

[15]  Jing Li,et al.  Discovery and identification of potential biomarkers of pediatric Acute Lymphoblastic Leukemia , 2009, Proteome Science.

[16]  L. Cazares,et al.  Differential Capture of Serum Proteins for Expression Profiling and Biomarker Discovery in Pre‐ and Posttreatment Head and Neck Cancer Samples , 2008, The Laryngoscope.

[17]  S. Matsumoto,et al.  Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus , 2007, Journal of gastroenterology and hepatology.

[18]  R. Robbins,et al.  Serum peptide profiling: identifying novel cancer biomarkers for early disease detection. , 2007, Acta bio-medica : Atenei Parmensis.

[19]  Gil Alterovitz,et al.  Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease , 2007, Proceedings of the National Academy of Sciences.

[20]  Cornelis J H van de Velde,et al.  Detection of colorectal cancer using MALDI-TOF serum protein profiling. , 2006, European journal of cancer.

[21]  E. Estey,et al.  Proteomic‐based prediction of clinical behavior in adult acute lymphoblastic leukemia , 2006, Cancer.

[22]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[23]  B. Ni,et al.  Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis. , 2005, Leukemia research.

[24]  Chun-Ta Liao,et al.  Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. , 2005, Clinical chemistry.

[25]  Nilanjan Chatterjee,et al.  Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Wei Li,et al.  Proteomics-based Identification of Human Acute Leukemia Antigens That Induce Humoral Immune Response* , 2005, Molecular & Cellular Proteomics.

[27]  A. Hershko,et al.  The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle* , 2005, Cell Death and Differentiation.

[28]  I. Dryden,et al.  Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Ralf Ketterlinus,et al.  Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. , 2005, BioTechniques.

[30]  S. Baumann,et al.  Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2005, Clinical chemistry.

[31]  A. Seth,et al.  The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. , 2004, European journal of cancer.

[32]  G. Gatta,et al.  Adult acute myeloid leukaemia. , 2004, Critical reviews in oncology/hematology.

[33]  E. Holland,et al.  Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.

[34]  D. Jackson,et al.  Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. , 2002, Cancer research.

[35]  T. Bugge,et al.  Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. , 2000, Blood.

[36]  D. McMillan,et al.  Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. , 1998, The Journal of nutrition.

[37]  M. Scheffner,et al.  Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.